Adagene Announces Dosing of First Patient in Phase 1 Study of Muzastotug in Combination with Incyte’s INCA33890 in Patients with Microsatellite Stable Colorectal Cancer
Key Highlights
- ➤First patient dosed in Phase 1 muzastotug–INCA33890 combination study
- ➤Trial targets third-line MSS colorectal cancer patients with and without liver metastases
- ➤Incyte sponsors and conducts study; Adagene supplies clinical muzastotug
- ➤Study evaluates open-label dose escalation and expansion after prior therapies
Expert Statements
Peter Luo, Ph.D., Chairman and President of R&D at Adagene
“Building on the clinical activity observed with muzastotug plus pembrolizumab, this study will evaluate whether adding muzastotug to Incyte’s TGFβR2 × PD-1 bispecific can deepen and sustain antitumor responses in MSS colorectal cancer, including patients with liver metastases”
Peter Luo, Ph.D., Chairman and President of R&D at Adagene
“The combination brings together muzastotug’s intended intratumoral Treg-depleting activity and INCA33890’s inhibition of two pathways that suppress T-cell function”
Peter Luo, Ph.D., Chairman and President of R&D at Adagene
“The study will assess whether these complementary mechanisms can broaden clinical benefit with an acceptable safety profile based on the optimized doses in combination with PD-1”
Peter Luo, Ph.D., Chairman and President of R&D at Adagene
“The strength of muzastotug as a potential backbone therapy for multiple indications continues to be recognized through several collaborations with leading biopharmaceutical companies, reflecting its differentiated safety profile relative to legacy CTLA-4 therapies”
Phase 1 study to evaluate the combination of muzastotug, a masked anti-CTLA-4 SAFEbody, and INCA33890, Incyte’s TGFβR2 × PD-1 bispecific antibody, in 3L MSS CRC patients with and without liver metastases
SAN DIEGO and SUZHOU, China, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies, today announced the dosing of the first patient in a Phase 1 study evaluating the combination of muzastotug and INCA33890, Incyte’s TGFβR2 × PD-1 bispecific antibody, in patients with microsatellite stable colorectal cancer (MSS CRC).
Get started
Create a free account to read the full story.